How many stocks are there of Biontech?
The current number of stocks of Biontech is 242.7 M undefined.
Biontech Stocks 2024
Biontech Stocks
242.7 M
Ticker
BNTX
ISIN
US09075V1026
WKN
A2PSR2
In 2024, Biontech had 242.7 M outstanding stocks, a 0% change from the 242.7 M stocks in the previous year.
The Biontech Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2029e | 242.7 |
| 2028e | 242.7 |
| 2027e | 242.7 |
| 2026e | 242.7 |
| 2025e | 242.7 |
| 2024e | 242.7 |
| 2023 | 242.7 |
| 2022 | 250 |
| 2021 | 260 |
| 2020 | 253 |
| 2019 | 211 |
| 2018 | 226 |
| 2017 | 226 |
Biontech shares outstanding US09075V1026 · A2PSR2
The number of shares was Biontech in 2023 — This indicates how many shares 242.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Biontech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Biontech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Biontech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biontech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2017 | 226 M Aktien |
| 2018 | 226 M Aktien |
| 2019 | 211 M Aktien |
| 2020 | 253 M Aktien |
| 2021 | 260 M Aktien |
| 2022 | 250 M Aktien |
| 2023 | 242.7 M Aktien |
| 2024e | 242.7 M Aktien |
| 2025e | 242.7 M Aktien |
| 2026e | 242.7 M Aktien |
| 2027e | 242.7 M Aktien |
| 2028e | 242.7 M Aktien |
| 2029e | 242.7 M Aktien |
Biontech Aktienanalyse
What does Biontech do?
BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Biontech's Shares Outstanding
Biontech's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Biontech’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Biontech’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Biontech’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Biontech stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Biontech are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Biontech evolved in recent years?
The number of shares of Biontech has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Biontech as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Biontech?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Biontech pay?
Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 1.91 %. For the coming 12 months, Biontech is expected to pay a dividend of -0.19 EUR.
What is the dividend yield of Biontech?
The current dividend yield of Biontech is 1.91 %.
When does Biontech pay dividends?
Biontech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biontech?
Biontech paid dividends every year for the past 2 years.
What is the dividend of Biontech?
For the upcoming 12 months, dividends amounting to -0.19 EUR are expected. This corresponds to a dividend yield of -0.17 %.
In which sector is Biontech located?
Biontech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.
When did Biontech pay the last dividend?
The last dividend was paid out on 6/17/2022.
What was the dividend of Biontech in the year 2023?
In the year 2023, Biontech distributed 2.132 EUR as dividends.
In which currency does Biontech pay out the dividend?
The dividends of Biontech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biontech stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
